Tirzepatide
Tirzepatide is a novel, synthetic, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist under investigation for its potential in treating type 2 diabetes and obesity. By combining the actions of GIP and GLP-1, Tirzepatide aims to improve glycemic control and promote weight loss more effectively than existing monotherapies. This dual agonist approach enhances insulin secretion, suppresses glucagon levels, and slows gastric emptying, contributing to improved metabolic outcomes.
Tirzepatide is a novel, synthetic, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist under investigation for its potential in treating type 2 diabetes and obesity. By combining the actions of GIP and GLP-1, Tirzepatide aims to improve glycemic control and promote weight loss more effectively than existing monotherapies. This dual agonist approach enhances insulin secretion, suppresses glucagon levels, and slows gastric emptying, contributing to improved metabolic outcomes.
Tirzepatide is a novel, synthetic, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist under investigation for its potential in treating type 2 diabetes and obesity. By combining the actions of GIP and GLP-1, Tirzepatide aims to improve glycemic control and promote weight loss more effectively than existing monotherapies. This dual agonist approach enhances insulin secretion, suppresses glucagon levels, and slows gastric emptying, contributing to improved metabolic outcomes.